Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines

Saudi Medical Journal

Volumn 34, Issue 11, 2013, Pages 1145-1150

  Hussain, Saad A ^a   Marouf, Bushra H ^b  

^a UNIVERSITY OF BAGHDAD   (Iraq)

^b UNIVERSITY OF SULAIMANI   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; SILIBININ; TETRAZOLIUM;

ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; RHABDOMYOSARCOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; METHOTREXATE; RHABDOMYOSARCOMA; SILYMARIN;

EID: 84888878711     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Weinstein RS, Jakate SM, Dominguez JM. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991; 51: 2720-2726.
2. De Larco JE, Wuertz BR, Manivel JC. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001; 61: 2857-2861.
3. Bertino JR. Karnofsky memorial lecture: ode to methotrexate. J Clin Oncol 1993; 11: 5-14.
4. Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-1960.
5. Fabre G, Fabre I, Matherly LH, Cano JP, Goldman ID. Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. J Biol Chem 1984; 259: 5066-5072.
6. Fabre G, Matherly LH, Favre R, Catalin J, Cano JP. In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells. Cancer Res 1983; 43: 4648-4652.
7. Rots MG, Pieters R, Kaspers GJ, Veerman AJ, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukemia. Br J Haematol 2000; 110: 791-800.
8. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999; 19: 91-122.
9. Stark M, Rothem L, Jansen G, Scheffer GL, Goldman ID, Assaraf YG. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol Pharmacol 2003; 64: 220-227.
10. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-780.
11. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-113.
12. Varghese L, Agarwal C, Tyagi A. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 2005; 11: 8441-8448.
13. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006; 25: 1053-1069.
14. Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 2004; 11: 493-499.
15. Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer 2003; 106: 699-705.
16. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002; 8: 3512-3519.
17. Flaig TW, Su LJ, Harrison G, Agarwal R, Glode LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer 2007; 120: 2028-2033.
18. Cocker HA, Pinkerton CR, Kelland LR. Characterization and modulation of drug resistance of human pediatric rhabdomyosarcoma cell lines. Br J Cancer 2000; 83: 338-345.
19. Selga E, Noe V, Ciudad CJ. Transcriptional regulation of aldo-ketoreductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol 2008; 75: 414-426.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
21. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
22. Kong JM, Goh NK, Chia LS, Chia TF. Recent advances in traditional plant drugs and orchids. Acta Pharmacol Sin 2003; 24: 7-21.
23. Lah JJ, Cui W, Hu KQ. Effects and mechanisms of Silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13: 5299-5305.
24. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 2006; 12: 2944-2950.
25. Kauntz H, Bousserouel S, Gosse F, Raul F. Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells. Apoptosis 2011; 16: 1042-1053.
26. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004; 25: 1711-1720.
27. Xie X, Yin J, Jia Q, Wang J, Zou C, Brewer KJ, et al. Quercetin induces apoptosis in the methotrexate-resistant osteosarcoma cell line U2-OS/MTX300 via mitochondrial dysfunction and dephosphorylation of Akt. Oncol Rep 2011; 26: 687-693.
28. Deep G, Agarwal R. New combination therapies with cell-cycle agents. Curr Opin Invest Drugs 2008; 9: 591-604.
29. Gazak R, Svobodova A, Psotova J, Sedmera P, Prikrylova V, Walterova D, et al. Oxidised derivatives of Silybin and their antiradical and antioxidant activity. Bioorg Med Chem 2004; 12: 5677-5687.
30. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010; 29: 447-463.
31. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC. Influence of methotrexate dose intensity on outcome of patients with high-grade osteogenic osteosarcoma. Analysis of the literature. Cancer 1996; 78: 2127-2135.
32. Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 2005; 41: 1969-1979.
33. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS. A phase I and pharmacokinetic study of silybinphytosome in prostate cancer patients. Invest New Drugs 2007; 25: 139-146.
34. Mulrow C, Lawrence V, Jacobs B, Dennehy C, Sapp J, Ramirez G, et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evid Rep Technol Assess 2000; 21: 1-3.
35. Zhou L, Liu P, Chen B, Wang Y, Wang X, Internati MC, et al. Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Res 2008; 28: 1119-1127.
36. Karim BO, Rhee KJ, Liu G, Zheng D, Huso DL. Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc-/+ mice. BMC Cancer 2013; 13: 157-167.
37. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007; 6: 3248-3255.
38. Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 2008; 14: 300-308.
39. Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang Z, et al. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 2011; 10: 104-116.
40. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27: 17-24.
41. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009; 12: 46-78.